farmatic biotech energy AG

2000. Capital Stage invested an undisclosed sum after the company’s IPO in April 2000

Hamburg-based Capital Stage has completed a partial exit via a trade sale from its investment in farmatic biotech energy AG. The venture capital firm sold 8.85% of its 17.7% equity stake in the company for cash to an unnamed strategic investor. The profits for Capital Stage were EUR 7.63m. Carsten Stold arranged the transaction on behalf of Capital Stage.

In 2001 North Germany’s farmatic biotech energy made a turnover of EUR 35m and EBIT of EUR 1.9%. Originally founded as a wastewater technology engineering business in 1963, the firm expanded its portfolio towards the end of the 1990s to include biogas recycling. Today the company currently develops a new technology that will allow the recycling of biogas to reach the same quality as natural gas.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH